LGD-4033 vs PEG-MGF
A side-by-side research comparison of LGD-4033 and PEG-MGF across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | LGD-4033 | PEG-MGF |
|---|---|---|
| Full name | Ligandrol (LGD-4033) | PEGylated Mechano Growth Factor |
| Category | Muscle Growth | Muscle Growth |
| Status | Investigational | Research compound |
| Mechanism | Selectively binds androgen receptors in muscle and bone, activating anabolic gene transcription while avoiding prostate activity. | PEGylation protects MGF from rapid degradation, extending half-life from minutes to hours. Activates satellite cells systemically for whole-body muscle recovery. |
| Molecular weight | 338.25 Da | ~5000 Da (with PEG) |
| Half-life | ~24-36 hours | ~30 minutes to several hours (vs 5-7 min native) |
| Bioavailability | ~90% oral | ~85% subcutaneous |
| Typical dose | 5-10 mg | 100-200 mcg |
| Frequency | Once daily | 2-3x per week |
| Route | Oral | Subcutaneous injection |
LGD-4033 reported benefits
- Significant lean mass gains
- Bone density improvement
- Oral convenience
- Selective tissue activity
PEG-MGF reported benefits
- Extended half-life vs native MGF
- Systemic satellite cell activation
- Whole-body recovery
- Less frequent dosing
Related comparisons
Research and educational reference only. Not medical advice.